Caricamento...
Pembrolizumab for non‐small cell lung cancer with central nervous system metastases: A two‐case report
Non‐small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. Central nervous system metastases are a common complication of NSCLC and confer a poor prognosis and a dismal survival rate. Treatment is limited, has poor outcomes, and affects patient quality of life. Pembrolizumab is a...
Salvato in:
| Pubblicato in: | Thorac Cancer |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons Australia, Ltd
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6360200/ https://ncbi.nlm.nih.gov/pubmed/30614652 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12963 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|